eligibility_summary
Adults 18–70 with EBV‑positive advanced cancer after failure of second‑line standard therapy (incl. PD‑1), ECOG 0–2, life expectancy ≥3 months, adequate hematologic, hepatic, renal function and LVEF ≥50%, consent/follow‑up. Exclude recent trial participation, other active cancers (except certain cured), serious heart disease, pregnancy, active TB/infections, HIV with active HBV/HCV, substance/psychiatric issues, active autoimmune disease (some exceptions), or unsafe comorbidities.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial NCT05707910 tests a biological “EBV immunological agent” (therapeutic vaccine/APC-based immunotherapy) given subcutaneously. Mechanism: the agent is naturally loaded with EBV antigens and enhances antigen presentation, activating dendritic cells and priming EBV‑specific CD4+/CD8+ T cells to mount cytotoxic responses against EBV‑positive tumor cells. Targets: immune APC/T-cell axis (dendritic cells, TCR-mediated T-cell activation) and tumor cells expressing EBV viral antigens, pathways include antigen presentation and T-cell effector activation. Note: the record lists “toripalimab” as an alias, toripalimab is a PD‑1–blocking monoclonal antibody, but the investigational product here is the EBV antigen–presenting biologic.